Search Results
May 06, 2026, 08:08 ET Valion Bio Celebrates Grand Opening of Velocity Bioworks Biomanufacturing Facility in San Antonio, Anchoring Domestic Production of Entolimod™
matter of hours.Today's ribbon cutting marks the operational beginning of Velocity Bioworks as both an internal manufacturing engine for Valion Bio's pipeline and an emerging contract development and manufacturing organization (CDMO) serving third-party biologics clients.About Valion Bio,
More news about: Valion Bio, Inc.
May 06, 2026, 08:00 ET Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon™ Technology
settings. The addition of Surf Bio's polymer‑based hyperconcentration technology further broadens the range of biologics that can be delivered subcutaneously, meaningfully expanding the scope of opportunities across therapeutic modalities. Together, Hypercon™ and Surf Bio's technology complement ENHANZE®
More news about: Halozyme Therapeutics, Inc.
May 05, 2026, 13:39 ET Odditt Launches B2B Platform That Generates 100,000+ Sportsbook Parlays a Day
or API integrations. Content can be customized by brand and filtered across thousands of categories, including weather, streaks, rivalries, player bios, and team metadata.Odditt's CTO and Co-Founder, Elaine Milardo, was DraftKings' first data hire and helped scale its data organization from one
More news about: Odditt
May 05, 2026, 10:09 ET Banyan BioInnovations Launches as an Investment Firm to Support Clinical-Stage Drug Assets, Secures More Than $100M in Initial Commitments from Life Science Investors
development team and turnkey infrastructure to optimize clinical and regulatory execution, guiding each asset through key value inflection points. Banyan Bio's differentiated and collaborative approach ensures that the drug's originator, investors, our NewCos, and patients all win together. For more information,
More news about: Banyan BioInnovations
May 05, 2026, 10:05 ET Creatv Announces Five Clinical Data Presentations at ASCO 2026
bevacizumab for patients with refractory metastatic colorectal cancer (mCRC): The phase 2 CLOVER study.Abstract: e13109Creatv Bio's LifeTracDx® blood test, described in the abstracts above, was used in the various studies to rapidly develop companion/complementary diagnostic
More news about: Creatv MicroTech, Inc.
May 05, 2026, 08:00 ET VALION BIO RECEIVES FIRST FDA-PRECEDENT STUDY PROTOCOL FROM NIAID FOR ENTOLIMOD™; FEDERAL AGENCY TO FULLY FUND BLA-ENABLING IN VIVO PROGRAM AND CO-NAVIGATE FDA SUBMISSION
remaining on the critical path to BLA filing, including bridging studies designed to confirm that Entolimod™ manufactured at Velocity Bioworks, Valion Bio's wholly owned CDMO subsidiary in San Antonio, is equivalent to drug material previously evaluated. Entolimod™ has been administered in 42 non-human primate
More news about: Tivic Health Systems, Inc.
May 05, 2026, 06:59 ET Q32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
observed to date in Part B of the SIGNAL-AA Phase 2a clinical trial, Q32 Bio's expectations and assumptions regarding the timing of reporting the findings from the Part A OLE of the SIGNAL-AA Phase 2a clinical trial, and Q32 Bio's beliefs, expectations and assumptions regarding the future of its business,
More news about: Q32 Bio
May 04, 2026, 16:10 ET Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update
Nuvation Bio's expectations that the MAA filing for taletrectinib will follow a standard review timeline and be considered for full approval, the need for new therapeutic options in IDH1-mutant gliomas, Nuvation Bio's plans for safusidenib development and future data presentations, and Nuvation Bio's evaluation
More news about: Nuvation Bio Inc.
May 04, 2026, 16:05 ET Valion Bio Appoints Melinda Lackey as General Counsel
across clinical-stage biopharmaceutical development, intellectual property strategy, and Nasdaq public company governance, a profile built for Valion Bio's current phase of growth.
More news about: Valion Bio, Inc.
May 04, 2026, 13:17 ET GIGABYTE Unveils Z890 PLUS Series Motherboards: Elite Gaming Performance Meets Exceptional Value
also introduces Ultra Turbo Mode across the Z890 PLUS series, delivering a powerful BIOS-level enhancement designed to maximize platform performance with minimal effort. With a single click in BIOS, users can boost CPU performance by up to 40% while enabling DDR5 memory overclocking
More news about: GIGABYTE
May 04, 2026, 09:44 ET Converge Bio uses ConvergeAB to improve popular cancer treatment with a single prompt
offering a more efficient path to refining existing drug offerings, with less reliance on traditional trial-and-error methods. The work reflects Converge Bio's broader vision of building a "computational lab of the future," where AI can simulate, test, and refine ideas digitally before they reach the lab. This
More news about: Converge Bio
May 01, 2026, 09:03 ET Matrix Introduces New Food For Soft XXL Big 'N Soft Mousse to Deliver Volume with 12-Hour Teddy Bear Softness
professional salons nationwide.For media inquiries, including stylist or executive quotes, additional background on the ambassador program, ambassador bios, hi-res imagery, or samples, please contact [email protected]
More news about: Matrix
Apr 30, 2026, 17:44 ET Rosalind Franklin University Helix 51 Incubator Company BLR Bio Presents Promising New Scleroderma Drug Data at International Rheumatology Meeting
scleroderma, with global figures ranging from 1.5 million to 2.5 million people. There are no FDA-approved therapies for scleroderma of the skin.BLR Bio's newly presented data serves to further elucidate both the mechanism of action and efficacy of BLR-200 in a bleomycin-induced in vivo model of systemic
More news about: Rosalind Franklin University of Medicine and Science
Apr 30, 2026, 16:30 ET Halozyme to Report First Quarter 2026 Financial and Operating Results
Merus N.V. and Skye Bioscience.Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon™ and Surf Bio's hyperconcentration technology. Hypercon™ is an innovative microparticle technology expected to set a new standard in hyperconcentration of drugs and
More news about: Halozyme Therapeutics, Inc.
Apr 30, 2026, 08:00 ET Halozyme Appoints Darren Snellgrove as Chief Financial Officer
settings. The addition of Surf Bio's polymer‑based hyperconcentration technology further broadens the range of biologics that can be delivered subcutaneously, meaningfully expanding the scope of opportunities across therapeutic modalities. Together, Hypercon™ and Surf Bio's technology complement ENHANZE®
More news about: Halozyme Therapeutics, Inc.
Apr 29, 2026, 23:13 ET D3 Bio Presents KRAS Pipeline Updates at AACR 2026; Elisrasib (D3S-001), a Next-Generation KRAS G12C Inhibitor, Shows Strong Phase 2 Efficacy Across Multiple Tumor Types
consistent and robust clinical activity exhibited by elisrasib across various KRAS G12C–mutant tumors, reinforcing the strength and momentum of D3 Bio's expanding KRAS pipeline," commented Dr. George Chen, Founder, Chairman and Chief Executive Officer of D3 Bio. "These data suggest elisrasib may become
More news about: D3 Bio
Apr 29, 2026, 17:16 ET MiTAC Computing sa vracia na OCP EMEA 2026 s novými servermi OCP chladenými kvapalinou a integráciou softvéru
podujatí predvedie spoločnosť MiTAC živé ukážky svojich najnovších firmvérových riešení s otvoreným zdrojom vrátane MiOPF, firmvéru pre hostiteľský systém (BIOS založený na EDK2), a MiOBMC, postaveného na distribúcii OpenBMC. Obe riešenia sú navrhnuté pre pokročilé prostredia IT a sú plne kompatibilné s DMTF
More news about: MiTAC Computing Technology Corp.
Apr 29, 2026, 17:11 ET MiTAC Computing возвращается на OCP EMEA 2026 с новыми серверами OCP с жидкостным охлаждением и интеграцией программного обеспечения
мероприятии MiTAC проведет живые демонстрации своих новейших микропрограмм с открытым исходным кодом, включая MiOPF, микропрограмму системного хоста (BIOS на основе EDK2) и MiOBMC, основанную на дистрибутиве OpenBMC. Оба решения предназначены для передовых ИТ-сред и полностью совместимы с DMTF Redfish,
More news about: MiTAC Computing Technology Corp.
Apr 29, 2026, 17:07 ET MiTAC Computing powraca na OCP EMEA 2026 z ofertą nowych serwerów OCP chłodzonych cieczą i integracji oprogramowania
MiTAC zaprezentuje na żywo najnowsze rozwiązania firmware oparte na otwartym kodzie źródłowym, w tym MiOPF - oprogramowanie układowe hosta systemowego (BIOS oparty na EDK2) - oraz MiOBMC bazujące na dystrybucji OpenBMC. Oba rozwiązania zostały zaprojektowane z myślą o zaawansowanych środowiskach IT i są
More news about: MiTAC Computing Technology Corp.
Apr 29, 2026, 17:01 ET MiTAC Computing regresa con novedades a OCP EMEA 2026
evento, MiTAC ofrecerá demostraciones en vivo de sus últimas soluciones de firmware de código abierto, incluyendo MiOPF, un firmware de host de sistema (BIOS basado en EDK2), y MiOBMC, basado en la distribución OpenBMC. Ambas soluciones están diseñadas para entornos de TI avanzados y son totalmente compatibles
More news about: MiTAC Computing Technology Corp.
Apr 29, 2026, 14:08 ET MiTAC Computing kehrt mit neuen OCP-Servern mit Flüssigkeitskühlung und Software-Integration zur OCP EMEA 2026 zurück
der Veranstaltung wird MiTAC Live-Vorführungen seiner neuesten Open-Source-Firmware-Lösungen durchführen, darunter MiOPF, eine System-Host-Firmware (BIOS auf Basis von EDK2), sowie MiOBMC, das auf der OpenBMC-Distribution basiert. Beide Lösungen sind für anspruchsvolle IT-Umgebungen konzipiert und vollständig
More news about: MiTAC Computing Technology Corp.
Apr 29, 2026, 13:52 ET MiTAC Computing revient à l'OCP EMEA 2026 avec de nouveaux serveurs OCP à refroidissement liquide et une intégration logicielle
MiTAC organisera des démonstrations en direct de ses dernières solutions de micrologiciels libres, notamment MiOPF, un micrologiciel hôte de système (BIOS basé sur EDK2), et MiOBMC, construit sur la distribution OpenBMC. Les deux solutions sont conçues pour les environnements informatiques avancés et sont
More news about: MiTAC Computing Technology Corp.
Apr 29, 2026, 04:00 ET MiTAC Computing Returns to OCP EMEA 2026 with New OCP Liquid Cooled Servers and Software Integration
principles.At the event, MiTAC will host live demonstrations of its latest open-source firmware solutions, including MiOPF, a system host firmware (BIOS based on EDK2), and MiOBMC, built on the OpenBMC distribution. Both solutions are designed for advanced IT environments and are fully compatible with
More news about: MiTAC Computing Technology Corp.
Apr 28, 2026, 08:01 ET VALION BIO BRIEFS PENTAGON LEADERSHIP ON ENTOLIMOD™ FOR ACUTE RADIATION SYNDROME
and civilian populations. We are committed to moving with the urgency this threat environment demands."The Pentagon briefing follows Valion Bio's recent selection for the Department of War's Tech Watch program and ongoing engagements with multiple U.S. government agencies regarding the inclusion
More news about: Valion Bio, Inc.
Apr 28, 2026, 08:00 ET Trinity Capital Inc. Provides $30 Million in Growth Capital to Iantrek to Accelerate Commercial Expansion and Advance Product Pipeline
Iantrek, a medical technology company and a leader in the bio-interventional ophthalmic surgery (BIOS) space.
More news about: Trinity Capital Inc.